

CLAIMS

1. A compound, or a pharmaceutically acceptable salt or solvate thereof, having the structure of **Formula (IA)** or **(IB)**:



Formula (IA)




Formula (IB)

wherein:

X is a bond, $-C(R^9)(R^{10})-$, $-N(R^{11})-$, -O-, $-S(O)_n-$, $-CH_2N(R^{11})-$, or $-CH_2O-$;

Y is a $-CH_2-$, $-CH_2CH_2-$, -CH=CH-, or $-CH_2OCH_2-$;


R^1 is , wherein ring A is a 5- or 6-membered heteroaryl ring or a 5- or 6-membered heterocycloalkyl ring optionally substituted with halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$, wherein the heteroaryl or heterocycloalkyl ring contains 1, 2 or 3 heteroatoms selected from the group consisting of O, N or S;

R^2 is hydrogen, deuterium, halogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl;

R^3 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl; or R^2 and R^3 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^4 and R^5 are independently selected from hydrogen, deuterium, halogen, and C_{1-3} alkyl; or R^3 and R^4 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^4 and R^5 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^6 and R^7 are independently selected from hydrogen, deuterium, halogen, and C_{1-3} alkyl; or R^3 and R^7 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^4 and R^6 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^5 and R^7 combine to form a bond;

R^8 is ;

R^9 and R^{10} are independently selected from hydrogen, deuterium, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl or heteroaryl; or R^3 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^4 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^6 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^9 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^{11} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl aryl or heteroaryl; or R^3 and R^{11} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^4 and R^{11} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^6 and R^{11} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

each R^{12} is independently selected from hydroxyl, halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$; or R^3 and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{10} and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with

halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{11} and one R^{12} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^{13} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl;

R^{14} and R^{15} are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl; or R^{14} and R^{15} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;


R^{16} is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl;

m is 0 or 1;

n is 0, 1, or 2; and

o is 0, 1, 2, or 3.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having the structure of **Formula** (**IIA**) or (**IIB**):






Formula (IIA) **Formula (IIB)**

wherein:

X is a bond, $-C(R^9)(R^{10})-$, $-N(R^{11})-$, $-O-$, $-S(O)_n-$, $-CH_2N(R^{11})-$, or $-CH_2O-$;


Y is a $-CH_2-$, $-CH_2CH_2-$, $-CH=CH-$, or $-CH_2OCH_2-$;

R^1 is , , or , wherein ring A is a 5- or 6-membered heteroaryl ring or a 5- or 6-membered heterocycloalkyl ring optionally substituted with halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-}

$_6$ alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$, wherein the heteroaryl or heterocycloalkyl ring contains 1, 2 or 3 heteroatoms selected from the group consisting of O, N or S;

R^2 is hydrogen, deuterium, halogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl;

R^3 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl; or R^2 and R^3 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^8 is ;

R^9 and R^{10} are independently selected from hydrogen, deuterium, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl or heteroaryl; or R^3 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^9 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^{11} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl aryl or heteroaryl; or R^3 and R^{11} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

each R^{12} is independently selected from hydroxyl, halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$; or R^3 and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{10} and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{11} and one R^{12} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^{13} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl;

R^{14} and R^{15} are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl; or R^{14} and R^{15} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;


R^{16} is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl;

m is 0 or 1;

n is 0, 1, or 2; and

o is 0, 1, 2, or 3.




3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having the structure of **Formula** (**III**):



Formula (III)


wherein:

X is a bond, $-C(R^9)(R^{10})-$, $-N(R^{11})-$, $-O-$, $-S(O)_n-$, $-CH_2N(R^{11})-$, or $-CH_2O-$;

R^1 is , , or , wherein ring A is a 5- or 6-membered heteroaryl ring or a 5- or 6-membered heterocycloalkyl ring optionally substituted with halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$, wherein the heteroaryl or heterocycloalkyl ring contains 1, 2 or 3 heteroatoms selected from the group consisting of O, N or S;

R^2 is hydrogen, deuterium, halogen, hydroxyl, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl;

R^3 is halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl or heteroaryl; or R^2 and R^3 combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^8 is ;

R^9 and R^{10} are independently selected from hydrogen, deuterium, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, heterocycloalkyl, aryl or heteroaryl; or R^3 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^9 and R^{10} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^{11} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl aryl or heteroaryl; or R^3 and R^{11} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

each R^{12} is independently selected from hydroxyl, halogen, cyano, $-N(R^{14})(R^{15})$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkoxy, C_{3-6} halocycloalkyl, C_{3-6} halocycloalkoxy, C_{1-6} alkylhydroxyl, heterocycloalkyl, aryl, heteroaryl, $-S(O)_n(R^{16})$, or $-SF_5$; or R^3 and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{10} and one R^{12} combine to form a cycloalkyl or heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{11} and one R^{12} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^{13} is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl;

R^{14} and R^{15} are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl; or R^{14} and R^{15} combine to form a heterocycloalkyl ring optionally substituted with halogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl;

R^{16} is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, C_{3-6} halocycloalkyl, heterocycloalkyl, aryl or heteroaryl;

m is 0 or 1;

n is 0, 1, or 2; and

o is 0, 1, 2, or 3.

4. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is a bond.

5. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is -C(R^9)(R^{10})-.




6. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is -N(R^{11})-.


7. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is -O-.

8. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is -S-.

9. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is -S(O)-.

10. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is -$S(O)_2$-.

11. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is 





, or .

12. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is hydrogen, -F, $-CH_3$, $-CH_2CH_3$, $-CF_2H$, $-CF_3$, $-CH_2OH$, $-C(CH_3)_2OH$, phenyl, or cyclopropyl.

13. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is -F, $-CH_3$, $-CH_2CH_3$, $-CF_2H$, $-CF_3$, $-CH_2OH$, $-C(CH_3)_2OH$, phenyl, or cyclopropyl.

14. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 and R^3 combine to form a cyclopropyl, cyclobutyl, or cyclopentyl ring.

15. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 and R^3 combine to form an oxetanyl or tetrahydrofuranyl ring.

16. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein m is 0.












17. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein m is 1.

18. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein o is 0.



19. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein o is 1.




20. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein o is 2.



21. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein o is 3.



22. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^8 is , , , , , , , , , , or .



23. A compound selected from:



, ,




, , ,




, ,



, ,



, ,



, ,



8 , , ,




9 , , ,



10 , ,



11 , ,



12 , ,




13 , ,




14 , , ,



15 , ,



16 , ,




17 , ,




18 , , ,




19 , , 




20 , ,




21 , ,




22 , , ,




23 , , 




24 , , ,




25 , , ,




26 , , ,




27 , , ,




28 , , ,




29 , , ,




30 , , ,




31 , , ,




32 , , ,




33 , , ,




34 , , ,




35 , , ,




36 , , ,




37 , , ,




38 , , ,




39 , , ,




40 , , ,




41 , , ,




42 , , ,




43 , , ,




44 , , ,




45 , , ,




46 , , ,




47 , , ,




48 , , ,




49 , , ,




50 , , ,



51 , , ,




52 , , ,




53 . , ,




54 , , ,




55 , , ,




56 , ,




57  ,  ,  ,




58  ,  ,  ,




59  ,  ,  ,




60  ,  ,  ,




61  ,  ,  ,




62  ,  ,  ,




63  ,  ,  ,




64  ,  ,  ,




65  ,  ,  ,




66  ,  ,  ,




67 , , ,




68 , , ,




69 , , ,




70 , , ,




71 , , ,




72 , , ,




73 , , ,




74 , , ,




75 , , ,



76 , , ,




77 , , ,




78 , , ,




79 , , ,




80 , , ,




81 , ,




82 , , ,




83 , , ,




84 , , ,




85 , , ,




86 , , ,




87 , , ,




88 , , ,




89 , , ,




90 , , ,




91 , , ,




92 , , ,




93 , , ,



94 , , ,




95 , , ,




96 , , ,




97 , , ,




98 , , ,




99 , ,




100 , , ,




101 , , ,




102 , , ,




103 , , ,




104 , , ,



105 , , ,



106 , , ,




107 , , ,




108 , , ,




109 , , ,




110 , ,




111 , ,


112 , , ,

113 , , ,

114 , , ,

115 , , ,

116 , , , and

117 ; or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising a compound of any one of claims 1-23, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.

26. Use of the compound of any one of claims 1-23, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of a neurodegenerative disorder in a subject in need thereof, wherein a therapeutically effective amount of the compound, or the pharmaceutically acceptable salt or solvate thereof, is to be administered to the subject.

27. The use of claim 26, wherein one or more immunomodulatory agents is to be administered.

28. The use of claim 27, wherein the one or more immunomodulatory agents are selected from: an IFN-β 1 molecule; a corticosteroid; a polymer of glutamic acid, lysine, alanine and tyrosine or glatiramer; an antibody or fragment thereof against alpha-4 integrin or natalizumab; an anthracenedione molecule or mitoxantrone; a fingolimod or FTY720 or other S1P1 functional modulator; a dimethyl fumarate or other NRF2 functional modulator; an antibody to the alpha subunit of the IL-2 receptor of T cells (CD25) or daclizumab; an antibody against CD52 or alemtuzumab; an antibody against CD20 or ocrelizumab; and an inhibitor of a dihydroorotate dehydrogenase or teriflunomide.

29. Use of the compound of any one of claims 1-23, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of a demyelinating disease in a subject in need thereof, wherein a therapeutically effective amount

of the compound, or the pharmaceutically acceptable salt or solvate thereof, is to be administered to the subject.

30. The use of claim 29, wherein the demyelinating disease is a demyelinating disease of the central nervous system.

31. The use of claim 30, wherein the demyelinating disease is multiple sclerosis.

32. The use of claim 29, wherein the demyelinating disease is a demyelinating disease of the peripheral nervous system.

33. The use of claim 29, wherein one or more immunomodulatory agents is to be administered.

34. The use of claim 33, wherein the one or more immunomodulatory agents are selected from: an IFN-β 1 molecule; a corticosteroid; a polymer of glutamic acid, lysine, alanine and tyrosine or glatiramer; an antibody or fragment thereof against alpha-4 integrin or natalizumab; an anthracenedione molecule or mitoxantrone; a fingolimod or FTY720 or other S1P1 functional modulator; a dimethyl fumarate or other NRF2 functional modulator; an antibody to the alpha subunit of the IL-2 receptor of T cells (CD25) or daclizumab; an antibody against CD52 or alemtuzumab; an antibody against CD20 or ocrelizumab; and an inhibitor of a dihydroorotate dehydrogenase or teriflunomide.

35. Use of the compound of any one of claims 1-23, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of a neuropathic disease, optionally a peripheral neuropathy, in a subject in need thereof, wherein a therapeutically effective amount of the compound, or the pharmaceutically acceptable salt or solvate thereof, is to be administered to the subject.

36. The use of claim 35, wherein the neuropathic disease is diabetic neuropathy.

37. The use of claim 35, wherein one or more immunomodulatory agents is to be administered.

38. The use of claim 37, wherein the one or more immunomodulatory agents are selected from: an IFN-β 1 molecule; a corticosteroid; a polymer of glutamic acid, lysine, alanine and tyrosine or glatiramer; an antibody or fragment thereof against alpha-4 integrin or natalizumab; an anthracenedione molecule or mitoxantrone; a fingolimod or FTY720 or other S1P1 functional modulator; a dimethyl fumarate or other NRF2 functional modulator; an antibody to the alpha subunit of the IL-2 receptor of T cells (CD25) or daclizumab; an antibody against CD52 or alemtuzumab; an antibody against CD20 or ocrelizumab; and an inhibitor of a dihydroorotate dehydrogenase or teriflunomide.

39. Use of the compound of any one of claims 1-23, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of a demyelinating disease in a subject, wherein the compound, or the pharmaceutically acceptable salt or solvate thereof, is to be administered to the subject, and wherein the compound, or the pharmaceutically acceptable salt or solvate thereof, is for modulating muscarinic acetylcholine receptor M_1 activity in the subject.

40. The use of claim 39, wherein the compound acts as a selective M_1 antagonist.